Xinlitai: SAL0195 Obtains Notification of Clinical Trial Approval

Xinlitai announced that the company recently received the "Clinical Trial Approval Notice" issued by the National Medical Products Administration, granting permission for the clinical trial of the self-developed innovative siRNA drug SAL0195 injection for the treatment of elevated lipoprotein levels. SAL0195 has shown a long-lasting effect in preclinical monkey models, achieving target knockdown for up to 140 days with a single administration.